Pancreatic cancer hENT1 expression and survival from gemcitabine in patients from the ESPAC-3 trial.
Identifieur interne : 003918 ( PubMed/Curation ); précédent : 003917; suivant : 003919Pancreatic cancer hENT1 expression and survival from gemcitabine in patients from the ESPAC-3 trial.
Auteurs : William Greenhalf ; Paula Ghaneh ; John P. Neoptolemos ; Daniel H. Palmer ; Trevor F. Cox ; Richard F. Lamb ; Elizabeth Garner ; Fiona Campbell ; John R. Mackey ; Eithne Costello ; Malcolm J. Moore ; Juan W. Valle ; Alexander C. Mcdonald ; Ross Carter ; Niall C. Tebbutt ; David Goldstein ; Jennifer Shannon ; Christos Dervenis ; Bengt Glimelius ; Mark Deakin ; Richard M. Charnley ; François Lacaine ; Andrew G. Scarfe ; Mark R. Middleton ; Alan Anthoney ; Christopher M. Halloran ; Julia Mayerle ; Attila Oláh ; Richard Jackson ; Charlotte L. Rawcliffe ; Aldo Scarpa ; Claudio Bassi ; Markus W. BüchlerSource :
- Journal of the National Cancer Institute [ 1460-2105 ] ; 2014.
Descripteurs français
- KwdFr :
- Adulte, Adulte d'âge moyen, Adénocarcinome (mortalité), Adénocarcinome (métabolisme), Adénocarcinome (traitement médicamenteux), Antinéoplasiques antimétabolites (usage thérapeutique), Désoxycytidine (analogues et dérivés), Désoxycytidine (usage thérapeutique), Estimation de Kaplan-Meier, Europe (épidémiologie), Femelle, Fluorouracil (administration et posologie), Humains, Leucovorine (administration et posologie), Marqueurs biologiques tumoraux (métabolisme), Mâle, Protocoles de polychimiothérapie antinéoplasique (usage thérapeutique), Résultat thérapeutique, Sujet âgé, Survie sans rechute, Transporteur équilibrant de nucléosides de type 1 (métabolisme), Tumeurs du pancréas (mortalité), Tumeurs du pancréas (métabolisme), Tumeurs du pancréas (traitement médicamenteux).
- MESH :
- administration et posologie : Fluorouracil, Leucovorine.
- analogues et dérivés : Désoxycytidine.
- mortalité : Adénocarcinome, Tumeurs du pancréas.
- métabolisme : Adénocarcinome, Marqueurs biologiques tumoraux, Transporteur équilibrant de nucléosides de type 1, Tumeurs du pancréas.
- traitement médicamenteux : Adénocarcinome, Tumeurs du pancréas.
- usage thérapeutique : Antinéoplasiques antimétabolites, Désoxycytidine, Protocoles de polychimiothérapie antinéoplasique.
- épidémiologie : Europe.
- Adulte, Adulte d'âge moyen, Estimation de Kaplan-Meier, Femelle, Humains, Mâle, Résultat thérapeutique, Sujet âgé, Survie sans rechute.
English descriptors
- KwdEn :
- Adenocarcinoma (drug therapy), Adenocarcinoma (metabolism), Adenocarcinoma (mortality), Adult, Aged, Antimetabolites, Antineoplastic (therapeutic use), Antineoplastic Combined Chemotherapy Protocols (therapeutic use), Biomarkers, Tumor (metabolism), Deoxycytidine (analogs & derivatives), Deoxycytidine (therapeutic use), Disease-Free Survival, Equilibrative Nucleoside Transporter 1 (metabolism), Europe (epidemiology), Female, Fluorouracil (administration & dosage), Humans, Kaplan-Meier Estimate, Leucovorin (administration & dosage), Male, Middle Aged, Pancreatic Neoplasms (drug therapy), Pancreatic Neoplasms (metabolism), Pancreatic Neoplasms (mortality), Treatment Outcome.
- MESH :
- chemical , administration & dosage : Fluorouracil, Leucovorin.
- chemical , analogs & derivatives : Deoxycytidine.
- chemical , metabolism : Biomarkers, Tumor, Equilibrative Nucleoside Transporter 1.
- chemical , therapeutic use : Antimetabolites, Antineoplastic, Deoxycytidine.
- geographic , epidemiology : Europe.
- drug therapy : Adenocarcinoma, Pancreatic Neoplasms.
- metabolism : Adenocarcinoma, Pancreatic Neoplasms.
- mortality : Adenocarcinoma, Pancreatic Neoplasms.
- therapeutic use : Antineoplastic Combined Chemotherapy Protocols.
- Adult, Aged, Disease-Free Survival, Female, Humans, Kaplan-Meier Estimate, Male, Middle Aged, Treatment Outcome.
Abstract
Human equilibrative nucleoside transporter 1 (hENT1) levels in pancreatic adenocarcinoma may predict survival in patients who receive adjuvant gemcitabine after resection.
DOI: 10.1093/jnci/djt347
PubMed: 24301456
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :003A47
Links to Exploration step
pubmed:24301456Curation
No country items
William Greenhalf<affiliation><nlm:affiliation>Affiliations of authors: Liverpool Cancer Research UK Cancer Trials Unit, Liverpool Cancer Research UK Centre, University of Liverpool, Liverpool, UK (WG, JPN, EG, TFC, PG, EC, CMH, CLR, FC, RJ); the Princess Margaret Hospital, Toronto, Canada (MJM); Manchester Academic Health Sciences Centre, Christie NHS Foundation Trust, School of Cancer and Enabling Sciences, University of Manchester, UK (JWV); Queen Elizabeth Hospital, University Hospital Birmingham NHS Foundation Trust, Birmingham, UK (DHP); Beatson West of Scotland Cancer Centre, Glasgow, UK (ACM); Glasgow Royal Infirmary, Glasgow, UK (RC); Hôpital Tenon, Université, Pierre et Marie Curie, Paris, France (FL); Austin Health, Melbourne, Australia (NCT); Prince of Wales Hospital and Clinical School University of New South Wales, New South Wales, Australia (DG); Nepean Cancer Centre and University of Sydney, Sydney, Australia (JS); Agia Olga Hospital, Athens, Greece (CD); Medical Oncology, Clatterbridge Centre for Oncology, Bebington, Merseyside, UK (DS); Department of Oncology, Akademiska Sjukhuset, Uppsala University, Uppsala, Sweden (BG); University Hospital, North Staffordshire, UK (MD); Freeman Hospital, Newcastle upon Tyne, UK (RMC); Service de Chirurgie Digestive et Viscérale, Hôpital Tenon, Paris, France (FL); Cross Cancer Institute and University of Alberta, Alberta, Canada (JRM, AGS); Churchill Hospital, Oxford University Hospitals NHS Trust, Oxford, UK (MRM); St James's University Hospital, Leeds, UK (AA); Department of Medicine A, University Medicine Greifswald, Greifswald, Germany (JM); Petz Aladar Hospital, Gyor, Hungary (AO); Departments of Surgery and Pathology and ARC-NET Research Center, University of Verona, Italy (AS, CB); Department of Surgery, University of Heidelberg, Heidelberg, Germany (MWB).</nlm:affiliation><wicri:noCountry code="subField">Germany (MWB)</wicri:noCountry></affiliation>Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Pancreatic cancer hENT1 expression and survival from gemcitabine in patients from the ESPAC-3 trial.</title><author><name sortKey="Greenhalf, William" sort="Greenhalf, William" uniqKey="Greenhalf W" first="William" last="Greenhalf">William Greenhalf</name><affiliation><nlm:affiliation>Affiliations of authors: Liverpool Cancer Research UK Cancer Trials Unit, Liverpool Cancer Research UK Centre, University of Liverpool, Liverpool, UK (WG, JPN, EG, TFC, PG, EC, CMH, CLR, FC, RJ); the Princess Margaret Hospital, Toronto, Canada (MJM); Manchester Academic Health Sciences Centre, Christie NHS Foundation Trust, School of Cancer and Enabling Sciences, University of Manchester, UK (JWV); Queen Elizabeth Hospital, University Hospital Birmingham NHS Foundation Trust, Birmingham, UK (DHP); Beatson West of Scotland Cancer Centre, Glasgow, UK (ACM); Glasgow Royal Infirmary, Glasgow, UK (RC); Hôpital Tenon, Université, Pierre et Marie Curie, Paris, France (FL); Austin Health, Melbourne, Australia (NCT); Prince of Wales Hospital and Clinical School University of New South Wales, New South Wales, Australia (DG); Nepean Cancer Centre and University of Sydney, Sydney, Australia (JS); Agia Olga Hospital, Athens, Greece (CD); Medical Oncology, Clatterbridge Centre for Oncology, Bebington, Merseyside, UK (DS); Department of Oncology, Akademiska Sjukhuset, Uppsala University, Uppsala, Sweden (BG); University Hospital, North Staffordshire, UK (MD); Freeman Hospital, Newcastle upon Tyne, UK (RMC); Service de Chirurgie Digestive et Viscérale, Hôpital Tenon, Paris, France (FL); Cross Cancer Institute and University of Alberta, Alberta, Canada (JRM, AGS); Churchill Hospital, Oxford University Hospitals NHS Trust, Oxford, UK (MRM); St James's University Hospital, Leeds, UK (AA); Department of Medicine A, University Medicine Greifswald, Greifswald, Germany (JM); Petz Aladar Hospital, Gyor, Hungary (AO); Departments of Surgery and Pathology and ARC-NET Research Center, University of Verona, Italy (AS, CB); Department of Surgery, University of Heidelberg, Heidelberg, Germany (MWB).</nlm:affiliation><wicri:noCountry code="subField">Germany (MWB)</wicri:noCountry></affiliation></author><author><name sortKey="Ghaneh, Paula" sort="Ghaneh, Paula" uniqKey="Ghaneh P" first="Paula" last="Ghaneh">Paula Ghaneh</name></author><author><name sortKey="Neoptolemos, John P" sort="Neoptolemos, John P" uniqKey="Neoptolemos J" first="John P" last="Neoptolemos">John P. Neoptolemos</name></author><author><name sortKey="Palmer, Daniel H" sort="Palmer, Daniel H" uniqKey="Palmer D" first="Daniel H" last="Palmer">Daniel H. Palmer</name></author><author><name sortKey="Cox, Trevor F" sort="Cox, Trevor F" uniqKey="Cox T" first="Trevor F" last="Cox">Trevor F. Cox</name></author><author><name sortKey="Lamb, Richard F" sort="Lamb, Richard F" uniqKey="Lamb R" first="Richard F" last="Lamb">Richard F. Lamb</name></author><author><name sortKey="Garner, Elizabeth" sort="Garner, Elizabeth" uniqKey="Garner E" first="Elizabeth" last="Garner">Elizabeth Garner</name></author><author><name sortKey="Campbell, Fiona" sort="Campbell, Fiona" uniqKey="Campbell F" first="Fiona" last="Campbell">Fiona Campbell</name></author><author><name sortKey="Mackey, John R" sort="Mackey, John R" uniqKey="Mackey J" first="John R" last="Mackey">John R. Mackey</name></author><author><name sortKey="Costello, Eithne" sort="Costello, Eithne" uniqKey="Costello E" first="Eithne" last="Costello">Eithne Costello</name></author><author><name sortKey="Moore, Malcolm J" sort="Moore, Malcolm J" uniqKey="Moore M" first="Malcolm J" last="Moore">Malcolm J. Moore</name></author><author><name sortKey="Valle, Juan W" sort="Valle, Juan W" uniqKey="Valle J" first="Juan W" last="Valle">Juan W. Valle</name></author><author><name sortKey="Mcdonald, Alexander C" sort="Mcdonald, Alexander C" uniqKey="Mcdonald A" first="Alexander C" last="Mcdonald">Alexander C. Mcdonald</name></author><author><name sortKey="Carter, Ross" sort="Carter, Ross" uniqKey="Carter R" first="Ross" last="Carter">Ross Carter</name></author><author><name sortKey="Tebbutt, Niall C" sort="Tebbutt, Niall C" uniqKey="Tebbutt N" first="Niall C" last="Tebbutt">Niall C. Tebbutt</name></author><author><name sortKey="Goldstein, David" sort="Goldstein, David" uniqKey="Goldstein D" first="David" last="Goldstein">David Goldstein</name></author><author><name sortKey="Shannon, Jennifer" sort="Shannon, Jennifer" uniqKey="Shannon J" first="Jennifer" last="Shannon">Jennifer Shannon</name></author><author><name sortKey="Dervenis, Christos" sort="Dervenis, Christos" uniqKey="Dervenis C" first="Christos" last="Dervenis">Christos Dervenis</name></author><author><name sortKey="Glimelius, Bengt" sort="Glimelius, Bengt" uniqKey="Glimelius B" first="Bengt" last="Glimelius">Bengt Glimelius</name></author><author><name sortKey="Deakin, Mark" sort="Deakin, Mark" uniqKey="Deakin M" first="Mark" last="Deakin">Mark Deakin</name></author><author><name sortKey="Charnley, Richard M" sort="Charnley, Richard M" uniqKey="Charnley R" first="Richard M" last="Charnley">Richard M. Charnley</name></author><author><name sortKey="Lacaine, Francois" sort="Lacaine, Francois" uniqKey="Lacaine F" first="François" last="Lacaine">François Lacaine</name></author><author><name sortKey="Scarfe, Andrew G" sort="Scarfe, Andrew G" uniqKey="Scarfe A" first="Andrew G" last="Scarfe">Andrew G. Scarfe</name></author><author><name sortKey="Middleton, Mark R" sort="Middleton, Mark R" uniqKey="Middleton M" first="Mark R" last="Middleton">Mark R. Middleton</name></author><author><name sortKey="Anthoney, Alan" sort="Anthoney, Alan" uniqKey="Anthoney A" first="Alan" last="Anthoney">Alan Anthoney</name></author><author><name sortKey="Halloran, Christopher M" sort="Halloran, Christopher M" uniqKey="Halloran C" first="Christopher M" last="Halloran">Christopher M. Halloran</name></author><author><name sortKey="Mayerle, Julia" sort="Mayerle, Julia" uniqKey="Mayerle J" first="Julia" last="Mayerle">Julia Mayerle</name></author><author><name sortKey="Olah, Attila" sort="Olah, Attila" uniqKey="Olah A" first="Attila" last="Oláh">Attila Oláh</name></author><author><name sortKey="Jackson, Richard" sort="Jackson, Richard" uniqKey="Jackson R" first="Richard" last="Jackson">Richard Jackson</name></author><author><name sortKey="Rawcliffe, Charlotte L" sort="Rawcliffe, Charlotte L" uniqKey="Rawcliffe C" first="Charlotte L" last="Rawcliffe">Charlotte L. Rawcliffe</name></author><author><name sortKey="Scarpa, Aldo" sort="Scarpa, Aldo" uniqKey="Scarpa A" first="Aldo" last="Scarpa">Aldo Scarpa</name></author><author><name sortKey="Bassi, Claudio" sort="Bassi, Claudio" uniqKey="Bassi C" first="Claudio" last="Bassi">Claudio Bassi</name></author><author><name sortKey="Buchler, Markus W" sort="Buchler, Markus W" uniqKey="Buchler M" first="Markus W" last="Büchler">Markus W. Büchler</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2014">2014</date><idno type="RBID">pubmed:24301456</idno><idno type="pmid">24301456</idno><idno type="doi">10.1093/jnci/djt347</idno><idno type="wicri:Area/PubMed/Corpus">003A47</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">003A47</idno><idno type="wicri:Area/PubMed/Curation">003918</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">003918</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Pancreatic cancer hENT1 expression and survival from gemcitabine in patients from the ESPAC-3 trial.</title><author><name sortKey="Greenhalf, William" sort="Greenhalf, William" uniqKey="Greenhalf W" first="William" last="Greenhalf">William Greenhalf</name><affiliation><nlm:affiliation>Affiliations of authors: Liverpool Cancer Research UK Cancer Trials Unit, Liverpool Cancer Research UK Centre, University of Liverpool, Liverpool, UK (WG, JPN, EG, TFC, PG, EC, CMH, CLR, FC, RJ); the Princess Margaret Hospital, Toronto, Canada (MJM); Manchester Academic Health Sciences Centre, Christie NHS Foundation Trust, School of Cancer and Enabling Sciences, University of Manchester, UK (JWV); Queen Elizabeth Hospital, University Hospital Birmingham NHS Foundation Trust, Birmingham, UK (DHP); Beatson West of Scotland Cancer Centre, Glasgow, UK (ACM); Glasgow Royal Infirmary, Glasgow, UK (RC); Hôpital Tenon, Université, Pierre et Marie Curie, Paris, France (FL); Austin Health, Melbourne, Australia (NCT); Prince of Wales Hospital and Clinical School University of New South Wales, New South Wales, Australia (DG); Nepean Cancer Centre and University of Sydney, Sydney, Australia (JS); Agia Olga Hospital, Athens, Greece (CD); Medical Oncology, Clatterbridge Centre for Oncology, Bebington, Merseyside, UK (DS); Department of Oncology, Akademiska Sjukhuset, Uppsala University, Uppsala, Sweden (BG); University Hospital, North Staffordshire, UK (MD); Freeman Hospital, Newcastle upon Tyne, UK (RMC); Service de Chirurgie Digestive et Viscérale, Hôpital Tenon, Paris, France (FL); Cross Cancer Institute and University of Alberta, Alberta, Canada (JRM, AGS); Churchill Hospital, Oxford University Hospitals NHS Trust, Oxford, UK (MRM); St James's University Hospital, Leeds, UK (AA); Department of Medicine A, University Medicine Greifswald, Greifswald, Germany (JM); Petz Aladar Hospital, Gyor, Hungary (AO); Departments of Surgery and Pathology and ARC-NET Research Center, University of Verona, Italy (AS, CB); Department of Surgery, University of Heidelberg, Heidelberg, Germany (MWB).</nlm:affiliation><wicri:noCountry code="subField">Germany (MWB)</wicri:noCountry></affiliation></author><author><name sortKey="Ghaneh, Paula" sort="Ghaneh, Paula" uniqKey="Ghaneh P" first="Paula" last="Ghaneh">Paula Ghaneh</name></author><author><name sortKey="Neoptolemos, John P" sort="Neoptolemos, John P" uniqKey="Neoptolemos J" first="John P" last="Neoptolemos">John P. Neoptolemos</name></author><author><name sortKey="Palmer, Daniel H" sort="Palmer, Daniel H" uniqKey="Palmer D" first="Daniel H" last="Palmer">Daniel H. Palmer</name></author><author><name sortKey="Cox, Trevor F" sort="Cox, Trevor F" uniqKey="Cox T" first="Trevor F" last="Cox">Trevor F. Cox</name></author><author><name sortKey="Lamb, Richard F" sort="Lamb, Richard F" uniqKey="Lamb R" first="Richard F" last="Lamb">Richard F. Lamb</name></author><author><name sortKey="Garner, Elizabeth" sort="Garner, Elizabeth" uniqKey="Garner E" first="Elizabeth" last="Garner">Elizabeth Garner</name></author><author><name sortKey="Campbell, Fiona" sort="Campbell, Fiona" uniqKey="Campbell F" first="Fiona" last="Campbell">Fiona Campbell</name></author><author><name sortKey="Mackey, John R" sort="Mackey, John R" uniqKey="Mackey J" first="John R" last="Mackey">John R. Mackey</name></author><author><name sortKey="Costello, Eithne" sort="Costello, Eithne" uniqKey="Costello E" first="Eithne" last="Costello">Eithne Costello</name></author><author><name sortKey="Moore, Malcolm J" sort="Moore, Malcolm J" uniqKey="Moore M" first="Malcolm J" last="Moore">Malcolm J. Moore</name></author><author><name sortKey="Valle, Juan W" sort="Valle, Juan W" uniqKey="Valle J" first="Juan W" last="Valle">Juan W. Valle</name></author><author><name sortKey="Mcdonald, Alexander C" sort="Mcdonald, Alexander C" uniqKey="Mcdonald A" first="Alexander C" last="Mcdonald">Alexander C. Mcdonald</name></author><author><name sortKey="Carter, Ross" sort="Carter, Ross" uniqKey="Carter R" first="Ross" last="Carter">Ross Carter</name></author><author><name sortKey="Tebbutt, Niall C" sort="Tebbutt, Niall C" uniqKey="Tebbutt N" first="Niall C" last="Tebbutt">Niall C. Tebbutt</name></author><author><name sortKey="Goldstein, David" sort="Goldstein, David" uniqKey="Goldstein D" first="David" last="Goldstein">David Goldstein</name></author><author><name sortKey="Shannon, Jennifer" sort="Shannon, Jennifer" uniqKey="Shannon J" first="Jennifer" last="Shannon">Jennifer Shannon</name></author><author><name sortKey="Dervenis, Christos" sort="Dervenis, Christos" uniqKey="Dervenis C" first="Christos" last="Dervenis">Christos Dervenis</name></author><author><name sortKey="Glimelius, Bengt" sort="Glimelius, Bengt" uniqKey="Glimelius B" first="Bengt" last="Glimelius">Bengt Glimelius</name></author><author><name sortKey="Deakin, Mark" sort="Deakin, Mark" uniqKey="Deakin M" first="Mark" last="Deakin">Mark Deakin</name></author><author><name sortKey="Charnley, Richard M" sort="Charnley, Richard M" uniqKey="Charnley R" first="Richard M" last="Charnley">Richard M. Charnley</name></author><author><name sortKey="Lacaine, Francois" sort="Lacaine, Francois" uniqKey="Lacaine F" first="François" last="Lacaine">François Lacaine</name></author><author><name sortKey="Scarfe, Andrew G" sort="Scarfe, Andrew G" uniqKey="Scarfe A" first="Andrew G" last="Scarfe">Andrew G. Scarfe</name></author><author><name sortKey="Middleton, Mark R" sort="Middleton, Mark R" uniqKey="Middleton M" first="Mark R" last="Middleton">Mark R. Middleton</name></author><author><name sortKey="Anthoney, Alan" sort="Anthoney, Alan" uniqKey="Anthoney A" first="Alan" last="Anthoney">Alan Anthoney</name></author><author><name sortKey="Halloran, Christopher M" sort="Halloran, Christopher M" uniqKey="Halloran C" first="Christopher M" last="Halloran">Christopher M. Halloran</name></author><author><name sortKey="Mayerle, Julia" sort="Mayerle, Julia" uniqKey="Mayerle J" first="Julia" last="Mayerle">Julia Mayerle</name></author><author><name sortKey="Olah, Attila" sort="Olah, Attila" uniqKey="Olah A" first="Attila" last="Oláh">Attila Oláh</name></author><author><name sortKey="Jackson, Richard" sort="Jackson, Richard" uniqKey="Jackson R" first="Richard" last="Jackson">Richard Jackson</name></author><author><name sortKey="Rawcliffe, Charlotte L" sort="Rawcliffe, Charlotte L" uniqKey="Rawcliffe C" first="Charlotte L" last="Rawcliffe">Charlotte L. Rawcliffe</name></author><author><name sortKey="Scarpa, Aldo" sort="Scarpa, Aldo" uniqKey="Scarpa A" first="Aldo" last="Scarpa">Aldo Scarpa</name></author><author><name sortKey="Bassi, Claudio" sort="Bassi, Claudio" uniqKey="Bassi C" first="Claudio" last="Bassi">Claudio Bassi</name></author><author><name sortKey="Buchler, Markus W" sort="Buchler, Markus W" uniqKey="Buchler M" first="Markus W" last="Büchler">Markus W. Büchler</name></author></analytic><series><title level="j">Journal of the National Cancer Institute</title><idno type="eISSN">1460-2105</idno><imprint><date when="2014" type="published">2014</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adenocarcinoma (drug therapy)</term><term>Adenocarcinoma (metabolism)</term><term>Adenocarcinoma (mortality)</term><term>Adult</term><term>Aged</term><term>Antimetabolites, Antineoplastic (therapeutic use)</term><term>Antineoplastic Combined Chemotherapy Protocols (therapeutic use)</term><term>Biomarkers, Tumor (metabolism)</term><term>Deoxycytidine (analogs & derivatives)</term><term>Deoxycytidine (therapeutic use)</term><term>Disease-Free Survival</term><term>Equilibrative Nucleoside Transporter 1 (metabolism)</term><term>Europe (epidemiology)</term><term>Female</term><term>Fluorouracil (administration & dosage)</term><term>Humans</term><term>Kaplan-Meier Estimate</term><term>Leucovorin (administration & dosage)</term><term>Male</term><term>Middle Aged</term><term>Pancreatic Neoplasms (drug therapy)</term><term>Pancreatic Neoplasms (metabolism)</term><term>Pancreatic Neoplasms (mortality)</term><term>Treatment Outcome</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adulte</term><term>Adulte d'âge moyen</term><term>Adénocarcinome (mortalité)</term><term>Adénocarcinome (métabolisme)</term><term>Adénocarcinome (traitement médicamenteux)</term><term>Antinéoplasiques antimétabolites (usage thérapeutique)</term><term>Désoxycytidine (analogues et dérivés)</term><term>Désoxycytidine (usage thérapeutique)</term><term>Estimation de Kaplan-Meier</term><term>Europe (épidémiologie)</term><term>Femelle</term><term>Fluorouracil (administration et posologie)</term><term>Humains</term><term>Leucovorine (administration et posologie)</term><term>Marqueurs biologiques tumoraux (métabolisme)</term><term>Mâle</term><term>Protocoles de polychimiothérapie antinéoplasique (usage thérapeutique)</term><term>Résultat thérapeutique</term><term>Sujet âgé</term><term>Survie sans rechute</term><term>Transporteur équilibrant de nucléosides de type 1 (métabolisme)</term><term>Tumeurs du pancréas (mortalité)</term><term>Tumeurs du pancréas (métabolisme)</term><term>Tumeurs du pancréas (traitement médicamenteux)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Fluorouracil</term><term>Leucovorin</term></keywords><keywords scheme="MESH" type="chemical" qualifier="analogs & derivatives" xml:lang="en"><term>Deoxycytidine</term></keywords><keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Biomarkers, Tumor</term><term>Equilibrative Nucleoside Transporter 1</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antimetabolites, Antineoplastic</term><term>Deoxycytidine</term></keywords><keywords scheme="MESH" type="geographic" qualifier="epidemiology" xml:lang="en"><term>Europe</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Fluorouracil</term><term>Leucovorine</term></keywords><keywords scheme="MESH" qualifier="analogues et dérivés" xml:lang="fr"><term>Désoxycytidine</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Adenocarcinoma</term><term>Pancreatic Neoplasms</term></keywords><keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Adenocarcinoma</term><term>Pancreatic Neoplasms</term></keywords><keywords scheme="MESH" qualifier="mortality" xml:lang="en"><term>Adenocarcinoma</term><term>Pancreatic Neoplasms</term></keywords><keywords scheme="MESH" qualifier="mortalité" xml:lang="fr"><term>Adénocarcinome</term><term>Tumeurs du pancréas</term></keywords><keywords scheme="MESH" qualifier="métabolisme" xml:lang="fr"><term>Adénocarcinome</term><term>Marqueurs biologiques tumoraux</term><term>Transporteur équilibrant de nucléosides de type 1</term><term>Tumeurs du pancréas</term></keywords><keywords scheme="MESH" qualifier="therapeutic use" xml:lang="en"><term>Antineoplastic Combined Chemotherapy Protocols</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Adénocarcinome</term><term>Tumeurs du pancréas</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Antinéoplasiques antimétabolites</term><term>Désoxycytidine</term><term>Protocoles de polychimiothérapie antinéoplasique</term></keywords><keywords scheme="MESH" qualifier="épidémiologie" xml:lang="fr"><term>Europe</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Aged</term><term>Disease-Free Survival</term><term>Female</term><term>Humans</term><term>Kaplan-Meier Estimate</term><term>Male</term><term>Middle Aged</term><term>Treatment Outcome</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adulte</term><term>Adulte d'âge moyen</term><term>Estimation de Kaplan-Meier</term><term>Femelle</term><term>Humains</term><term>Mâle</term><term>Résultat thérapeutique</term><term>Sujet âgé</term><term>Survie sans rechute</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Human equilibrative nucleoside transporter 1 (hENT1) levels in pancreatic adenocarcinoma may predict survival in patients who receive adjuvant gemcitabine after resection.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">24301456</PMID><DateCreated><Year>2014</Year><Month>01</Month><Day>09</Day></DateCreated><DateCompleted><Year>2014</Year><Month>02</Month><Day>28</Day></DateCompleted><DateRevised><Year>2015</Year><Month>11</Month><Day>19</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1460-2105</ISSN><JournalIssue CitedMedium="Internet"><Volume>106</Volume><Issue>1</Issue><PubDate><Year>2014</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Journal of the National Cancer Institute</Title><ISOAbbreviation>J. Natl. Cancer Inst.</ISOAbbreviation></Journal><ArticleTitle>Pancreatic cancer hENT1 expression and survival from gemcitabine in patients from the ESPAC-3 trial.</ArticleTitle><Pagination><MedlinePgn>djt347</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1093/jnci/djt347</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Human equilibrative nucleoside transporter 1 (hENT1) levels in pancreatic adenocarcinoma may predict survival in patients who receive adjuvant gemcitabine after resection.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Microarrays from 434 patients randomized to chemotherapy in the ESPAC-3 trial (plus controls from ESPAC-1/3) were stained with the 10D7G2 anti-hENT1 antibody. Patients were classified as having high hENT1 expression if the mean H score for their cores was above the overall median H score (48). High and low hENT1-expressing groups were compared using Kaplan-Meier curves, log-rank tests, and Cox proportional hazards models. All statistical tests were two-sided.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Three hundred eighty patients (87.6%) and 1808 cores were suitable and included in the final analysis. Median overall survival for gemcitabine-treated patients (n = 176) was 23.4 (95% confidence interval [CI] = 18.3 to 26.0) months vs 23.5 (95% CI = 19.8 to 27.3) months for 176 patients treated with 5-fluorouracil/folinic acid (χ(2) 1=0.24; P = .62). Median survival for patients treated with gemcitabine was 17.1 (95% CI = 14.3 to 23.8) months for those with low hENT1 expression vs 26.2 (95% CI = 21.2 to 31.4) months for those with high hENT1 expression (χ(2)₁= 9.87; P = .002). For the 5-fluorouracil group, median survival was 25.6 (95% CI = 20.1 to 27.9) and 21.9 (95% CI = 16.0 to 28.3) months for those with low and high hENT1 expression, respectively (χ(2)₁ = 0.83; P = .36). hENT1 levels were not predictive of survival for the 28 patients of the observation group (χ(2)₁ = 0.37; P = .54). Multivariable analysis confirmed hENT1 expression as a predictive marker in gemcitabine-treated (Wald χ(2) = 9.16; P = .003) but not 5-fluorouracil-treated (Wald χ(2) = 1.22; P = .27) patients.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Subject to prospective validation, gemcitabine should not be used for patients with low tumor hENT1 expression.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Greenhalf</LastName><ForeName>William</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Affiliations of authors: Liverpool Cancer Research UK Cancer Trials Unit, Liverpool Cancer Research UK Centre, University of Liverpool, Liverpool, UK (WG, JPN, EG, TFC, PG, EC, CMH, CLR, FC, RJ); the Princess Margaret Hospital, Toronto, Canada (MJM); Manchester Academic Health Sciences Centre, Christie NHS Foundation Trust, School of Cancer and Enabling Sciences, University of Manchester, UK (JWV); Queen Elizabeth Hospital, University Hospital Birmingham NHS Foundation Trust, Birmingham, UK (DHP); Beatson West of Scotland Cancer Centre, Glasgow, UK (ACM); Glasgow Royal Infirmary, Glasgow, UK (RC); Hôpital Tenon, Université, Pierre et Marie Curie, Paris, France (FL); Austin Health, Melbourne, Australia (NCT); Prince of Wales Hospital and Clinical School University of New South Wales, New South Wales, Australia (DG); Nepean Cancer Centre and University of Sydney, Sydney, Australia (JS); Agia Olga Hospital, Athens, Greece (CD); Medical Oncology, Clatterbridge Centre for Oncology, Bebington, Merseyside, UK (DS); Department of Oncology, Akademiska Sjukhuset, Uppsala University, Uppsala, Sweden (BG); University Hospital, North Staffordshire, UK (MD); Freeman Hospital, Newcastle upon Tyne, UK (RMC); Service de Chirurgie Digestive et Viscérale, Hôpital Tenon, Paris, France (FL); Cross Cancer Institute and University of Alberta, Alberta, Canada (JRM, AGS); Churchill Hospital, Oxford University Hospitals NHS Trust, Oxford, UK (MRM); St James's University Hospital, Leeds, UK (AA); Department of Medicine A, University Medicine Greifswald, Greifswald, Germany (JM); Petz Aladar Hospital, Gyor, Hungary (AO); Departments of Surgery and Pathology and ARC-NET Research Center, University of Verona, Italy (AS, CB); Department of Surgery, University of Heidelberg, Heidelberg, Germany (MWB).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ghaneh</LastName><ForeName>Paula</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Neoptolemos</LastName><ForeName>John P</ForeName><Initials>JP</Initials></Author><Author ValidYN="Y"><LastName>Palmer</LastName><ForeName>Daniel H</ForeName><Initials>DH</Initials></Author><Author ValidYN="Y"><LastName>Cox</LastName><ForeName>Trevor F</ForeName><Initials>TF</Initials></Author><Author ValidYN="Y"><LastName>Lamb</LastName><ForeName>Richard F</ForeName><Initials>RF</Initials></Author><Author ValidYN="Y"><LastName>Garner</LastName><ForeName>Elizabeth</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Campbell</LastName><ForeName>Fiona</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Mackey</LastName><ForeName>John R</ForeName><Initials>JR</Initials></Author><Author ValidYN="Y"><LastName>Costello</LastName><ForeName>Eithne</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Moore</LastName><ForeName>Malcolm J</ForeName><Initials>MJ</Initials></Author><Author ValidYN="Y"><LastName>Valle</LastName><ForeName>Juan W</ForeName><Initials>JW</Initials></Author><Author ValidYN="Y"><LastName>McDonald</LastName><ForeName>Alexander C</ForeName><Initials>AC</Initials></Author><Author ValidYN="Y"><LastName>Carter</LastName><ForeName>Ross</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Tebbutt</LastName><ForeName>Niall C</ForeName><Initials>NC</Initials></Author><Author ValidYN="Y"><LastName>Goldstein</LastName><ForeName>David</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Shannon</LastName><ForeName>Jennifer</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Dervenis</LastName><ForeName>Christos</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Glimelius</LastName><ForeName>Bengt</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Deakin</LastName><ForeName>Mark</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Charnley</LastName><ForeName>Richard M</ForeName><Initials>RM</Initials></Author><Author ValidYN="Y"><LastName>Lacaine</LastName><ForeName>François</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Scarfe</LastName><ForeName>Andrew G</ForeName><Initials>AG</Initials></Author><Author ValidYN="Y"><LastName>Middleton</LastName><ForeName>Mark R</ForeName><Initials>MR</Initials></Author><Author ValidYN="Y"><LastName>Anthoney</LastName><ForeName>Alan</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Halloran</LastName><ForeName>Christopher M</ForeName><Initials>CM</Initials></Author><Author ValidYN="Y"><LastName>Mayerle</LastName><ForeName>Julia</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Oláh</LastName><ForeName>Attila</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Jackson</LastName><ForeName>Richard</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Rawcliffe</LastName><ForeName>Charlotte L</ForeName><Initials>CL</Initials></Author><Author ValidYN="Y"><LastName>Scarpa</LastName><ForeName>Aldo</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Bassi</LastName><ForeName>Claudio</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Büchler</LastName><ForeName>Markus W</ForeName><Initials>MW</Initials></Author><Author ValidYN="Y"><CollectiveName>European Study Group for Pancreatic Cancer</CollectiveName></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>00/006</GrantID><Agency>Cancer Research UK</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>C245/A82390</GrantID><Agency>Cancer Research UK</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>SP1984/0204</GrantID><Agency>Cancer Research UK</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>SP2590/0101</GrantID><Agency>Cancer Research UK</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2013</Year><Month>12</Month><Day>03</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Natl Cancer Inst</MedlineTA><NlmUniqueID>7503089</NlmUniqueID><ISSNLinking>0027-8874</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000964">Antimetabolites, Antineoplastic</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014408">Biomarkers, Tumor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D033721">Equilibrative Nucleoside Transporter 1</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C438649">SLC29A1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0W860991D6</RegistryNumber><NameOfSubstance UI="D003841">Deoxycytidine</NameOfSubstance></Chemical><Chemical><RegistryNumber>B76N6SBZ8R</RegistryNumber><NameOfSubstance UI="C056507">gemcitabine</NameOfSubstance></Chemical><Chemical><RegistryNumber>Q573I9DVLP</RegistryNumber><NameOfSubstance UI="D002955">Leucovorin</NameOfSubstance></Chemical><Chemical><RegistryNumber>U3P01618RT</RegistryNumber><NameOfSubstance UI="D005472">Fluorouracil</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000230" MajorTopicYN="N">Adenocarcinoma</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000401" MajorTopicYN="Y">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000964" MajorTopicYN="N">Antimetabolites, Antineoplastic</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000971" MajorTopicYN="N">Antineoplastic Combined Chemotherapy Protocols</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014408" MajorTopicYN="N">Biomarkers, Tumor</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003841" MajorTopicYN="N">Deoxycytidine</DescriptorName><QualifierName UI="Q000031" MajorTopicYN="Y">analogs & derivatives</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018572" MajorTopicYN="N">Disease-Free Survival</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D033721" MajorTopicYN="N">Equilibrative Nucleoside Transporter 1</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005060" MajorTopicYN="N" Type="Geographic">Europe</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005472" MajorTopicYN="N">Fluorouracil</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053208" MajorTopicYN="N">Kaplan-Meier Estimate</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002955" MajorTopicYN="N">Leucovorin</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010190" MajorTopicYN="N">Pancreatic Neoplasms</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000401" MajorTopicYN="Y">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>12</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>12</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>3</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24301456</ArticleId><ArticleId IdType="pii">djt347</ArticleId><ArticleId IdType="doi">10.1093/jnci/djt347</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/PubMed/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003918 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 003918 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= PubMed
|étape= Curation
|type= RBID
|clé= pubmed:24301456
|texte= Pancreatic cancer hENT1 expression and survival from gemcitabine in patients from the ESPAC-3 trial.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i -Sk "pubmed:24301456" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd \
| NlmPubMed2Wicri -a AustralieFrV1
| This area was generated with Dilib version V0.6.33. |  |